A5037149561- Inflammatory Bowel Disease
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Apelin-related biomedical research
- Inflammatory mediators and NSAID effects
- Systemic Lupus Erythematosus Research
- Adipokines, Inflammation, and Metabolic Diseases
- Hormonal Regulation and Hypertension
- Computational Drug Discovery Methods
- Lipoproteins and Cardiovascular Health
- Osteoarthritis Treatment and Mechanisms
- Microscopic Colitis
- Cytokine Signaling Pathways and Interactions
- Stress Responses and Cortisol
AbbVie (United States)
2013-2024
Qingdao University
2023
Qingdao Municipal Hospital
2023
ABT-384 is a potent, selective inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 (HSD-1). One milligram daily fully inhibited hepatic HSD-1. Establishing the dose that inhibits central nervous system (CNS) HSD-1 would enable definitive clinical studies in potential CNS indications. [9,11,12,12-2H4] cortisol (D4 cortisol), stable labeled tracer, was used to characterize inhibition by ABT-384. D4 and its products were measured plasma cerebrospinal fluid (CSF) healthy male volunteers...
<h3>Background</h3> No approved OA therapies reduce pain and slow joint damage. Mouse data suggested that inhibiting IL-1α -1β with ABT-981 would structural progression in EHOA. <h3>Objectives</h3> To test the efficacy safety of <h3>Methods</h3> Subjects HOA per ACR criteria, ≥3 inflamed IP joints (tender, swollen, or both), hand ≥6 (scale 0–10), ≥1 erosive on X-ray (Verbruggen-Veys) were randomized to placebo (PBO) 200 mg SC every 2 wk for 26 wk. The primary outcome was AUSCAN at 16 had...
Abstract Background Risankizumab (RZB) has been evaluated in subjects with moderately to severely active ulcerative colitis (UC) the INSPIRE and COMMAND trials. Population pharmacokinetic (PPK) exposure-response (ER) analyses were conducted at end of Phase 2b following 3 characterize RZB PK its relationship clinical efficacy safety support induction dose selection, final recommendations for maintenance treatment. Methods PPK UC used a previously developed model Crohn’s disease additional...
Abstract Background Upadacitinib (UPA), an oral selective and reversible JAK1 inhibitor, showed favorable efficacy safety profile in Phase, 2b and, 3 studies subjects with moderate to severe ulcerative colitis (UC). Population pharmacokinetics exposure-response analyses were performed characterize the relationships between UPA plasma exposures key endpoints using data from these studies. Methods The (PK), efficacy, of for induction maintenance treatment UC evaluated a induction, two...
Abstract Background In order to support risankizumab dose recommendation for the treatment of Crohn’s disease (CD), population pharmacokinetic (PPK) and exposure-response (ER) analyses were conducted using data from Phases 2 & 3 studies in moderate severely active CD patients characterise PK its relationship with clinical efficacy safety. Methods PPK used non-linear mixed-effects modelling, leveraging a previously developed model plaque psoriasis CD, additional evaluation covariates...